Clinical study of paclitaxel combined with cisplatin in treatment of pulmonary metastasis tumor

ZHANG Ju

doi:10.13406/j.cnki.cyxb.2008.03.028

您当前的位置：

首页 >

文章列表页 >

Clinical study of paclitaxel combined with cisplatin in treatment of pulmonary metastasis tumor

更新时间：2024-01-17

- Clinical study of paclitaxel combined with cisplatin in treatment of pulmonary metastasis tumor
- Journal of Chongqing Medical University Issue 3, Pages: 364-366(2008)
- 作者机构：
  
  1. 重庆医科大学附属第一医院肿瘤科
  2. 重庆医科大学附属第一医院肿瘤科,重庆,400016
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.2008.03.028
  CLC： R730.5
- Published：2008，
扫描看全文
[1]张菊,任涛,陈晓品.紫杉醇联合顺铂治疗恶性肿瘤肺转移的临床研究[J].重庆医科大学学报,2008(03):364-366.

ZHANG Ju. Clinical study of paclitaxel combined with cisplatin in treatment of pulmonary metastasis tumor. [J]. Journal of Chongqing Medical University (3):364-366(2008)
[1]张菊,任涛,陈晓品.紫杉醇联合顺铂治疗恶性肿瘤肺转移的临床研究[J].重庆医科大学学报,2008(03):364-366. DOI： 10.13406/j.cnki.cyxb.2008.03.028.

ZHANG Ju. Clinical study of paclitaxel combined with cisplatin in treatment of pulmonary metastasis tumor. [J]. Journal of Chongqing Medical University (3):364-366(2008) DOI： 10.13406/j.cnki.cyxb.2008.03.028.

摘要

目的:观察紫杉醇（Paclitaxel

商品名Taxol）联合顺铂（TP方案）治疗恶性肿瘤肺转移的客观疗效及毒副反应。方法:40例恶性肿瘤肺转移的病人

采用TP方案化疗:紫杉醇135mg/m

静脉滴注

第1d;顺铂25mg/m

静脉滴注

第2～4d。4周为1个周期

均完成2周期以上。结果:40例患者中

完全缓解（CR）:17.5%（7/40）

部分缓解（PR）:45%（18/40）

稳定（sD）:27.5%（11/40）

进展（PD）:10%（4/40）

总有效率（CR+PR）:62.5%（25/40）。中位疾病进展时间为6个月

中位生存时间为10个月。主要毒副反应为骨髓抑制和脱发。结论:紫杉醇联合顺铂方案治疗恶性肿瘤肺转移的近期疗效较好

毒副反应可以耐受。

Abstract

Objective:To evaluate the effect and toxic side-effect of paclitaxel combined with cisplatin(TP regiment) chemotherapy in treatment of pulmonary metastasis tumor.Methods:Forty tumor patients with pulmonary metastasis accepted chemotherapy by paclitaxel 135mg/m~2 infusion intravenous on d1

and cisplatin 25mg/m~2 daily on d2～4.Each treatment cycle was four weeks.Each patient received more than 2 courses of treatment.Results:In 40 patients

7 were with complete response (17.5%)and 18 were with partial response(45%)

the complete remission and partial remission(CR+PR)was 62.5%;The disease kept stable in 11 case(27.5%)and progressed in 4 case(10%).The median time to tumor progression was 6.0months

and the median actuarial survival was10.0 months.The most common toxic side-effects were myelosuppression and alopecia. Conclusion:The combined chemotherapy of paclitaxel and cisplatin is good short-term efficacy in treatment of pulmonary metastasis tumor.The toxic side-effects are tolerable and mild.

关键词

紫杉醇联合化疗肺转移肿

Keywords

paclitaxelCombined chemotherapyPulmonary metastasis tumor

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Comparative study of VM₂₆and IFO regimen in advanced stage non-small-cell lung cancer

Clinical research of dose - dense combinated pharmorubicin with paclitaxel in advanced breast cancer treatment

FAT regiment for patients with relapsed,refractory acute leukemia

Inhibitory effect of low-dose paclitaxel combined with recombinant human endostatin on breast cancer MCF-7 cell line

intensity-modulated radiotherapy in the treatment of elderly patients with advanced cervical cancer and its impact on the quality of life and immune function

Related Author

薛亚梅

杜先智

蒋幼凡

王导新

et al

ZENG Xiaohua

王继见

余永康

Related Institution

重庆医科大学附属第二临床学院肺科

Department of Respiratory Medicine,Second College of Clinical M edicine,Chongqing Medical University

重庆医科大学附属第二医院普外科

Department of General,the Second Affiliated Hospital, Chongqing Mechical University

Department of Hematology,the Second Affiliated Hospital,Chongqing Medical University

⁰